Anabel Chan | Head, Investor Relations |
Mark Enyedy | President & Chief Executive Officer |
Anna Berkenblit | Chief Medical Officer |
Renee Lentini | Interim-Chief Financial Officer |
Michael Vasconcelles | Executive Vice President of Research, Development & Medical Affairs |
Todd Talarico | Vice President of Market Access |
John Newman | Canaccord Genuity |
Michael Schmidt | Guggenheim Partners |
Etzer Darout | BMO |
Andy Hsieh | William Blair |
Boris Peaker | Cowen |
Peter Lawson | Barclays |
Kelly Shi | Jefferies |
Asthika Goonewardene | Truist |
Joe Catanzaro | Piper Sandler |
Good morning and welcome to ImmunoGen's First Quarter 2023 Financial and Operating Results Conference Call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
Good morning, and thank you for joining today's call.